Table 2.

Standard deviation increments in creatinine-adjusted urinary osteopontin and plasma osteopontin and the associated 5-year progression of chronic kidney disease (logistic and linear regression models)

	Incidence		GFR decline
	urinary osteopontin	plasma osteopontin	urinary osteopontin	plasma osteopontin
Model A	1.16 (0.88 to 1.53)	1.24 (0.91 to 1.68)	−0.03 (−0.06 to −0.002)*	0.008 (−0.01 to 0.03)
Model B	1.48 (1.06 to 2.07)*	1.15 (0.82 to 1.61)	−0.02 (−0.05 to 0.005)	−0.009 (−0.03 to 0.01)
Model C	1.16 (0.87 to 1.53)	1.25 (0.90 to 1.74)	−0.03 (−0.06 to −0.002)*	0.005 (−0.02 to 0.03)
Model D	1.12 (0.83 to 1.51)	1.25 (0.92 to 1.70)	−0.03 (−0.06 to −0.0005)*	0.005 (−0.02 to 0.03)
Model E	1.42 (1.00 to 2.02)*	1.22 (0.84 to 1.77)	−0.02 (−0.05 to 0.008)	−0.01 (-0.03 to 0.01)

Values are odds ratios (95% confidence intervals) for incidence and regression coefficients (95% confidence intervals) for GFR decline. For the adjustments made in the models, see Statistical Analyses section. Incidence: plasma osteopontin, n = 347; urinary osteopontin, n = 241. GFR decline: plasma osteopontin, n = 413; urinary osteopontin, n = 293. GFR, glomerular filtration rate; model A, age-adjusted model; model B, kidney function model (model A + cystatin C-estimated GFR and albuminuria); model C, inflammation model (model A + C-reactive protein and interleukin 6); model D, cardiovascular risk factor model (model A + lipid-lowering treatment, cardiovascular diagnosis, body mass index, diabetes, antihypertensive treatments, systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, and smoking); model E, total model (combination of all variables included in model A-D).

^*Significance level: p < 0.05.